INTRODUCTION
Diabetes is now a well recognized complication of cystic fibrosis (CF). In 1938, Dorothy Andersen reviewed the case records and autopsy findings of 49 children in her classic paperl. She described several children with evidence of hyperinsulinism, as characterized by an abrupt increase in blood glucose, in response to dextrose tolerance tests, from low fasting levels to high values after I h, before an abrupt drop at 2 h. There was no mention of diabetes. It was not until 1955 when Shwachman provided the first description of diabetes associated with CF in three children2. Cystic fibrosis related diabetes (CFRD) was thought to be very rare in the past, but with the increasing longevity of CF patients this complication has become increasingly com-mon3. CFRD differs in many aspects from type 1 and type 2 diabetes4, and many questions related to aspects of CFRD remain unanswered. Research on CFRD has been hampered by a general lack of randomized controlled trials and the number of patients involved in clinical studies is generally small. In this paper, the authors would like to summarize various aspects of CFRD based on best available evidence and/or clinical practice at the Royal Brompton Hospital in London. EPIDEMIOLOGY CFRD is predominately a disease of adolescents and young adults and the prevalence increases with age3'5-7. Patients with CFRD present at a median age of around 20 years6' 8-9. There is a wide variation in the prevalence of CFRD reported in the literature and figures quoted vary from 2.5% to 24%5,6,8, 1 0,1. Such variation is probably related to the differences in the population studied, the age distribution of the study groups and the screening policy adopted, but also reflects the imprecision in the diagnostic criteria and the wide-ranging methods used in the diagnosis of CFRD.
We have reviewed the records of patients who had attended the Royal Brompton Hospital Adult CF Unit. At the end of 1996, 74 of the 518 patients attending (median age 26, range 16-59) had CFRD, thus the prevalence of CFRD at this unit was 14.3%. Patients presented at a median age of 21 years (range . We found a female predominance of patients with CFRD compared with a male predominance in the whole CF population, although this difference did not reach statistical significance (CFRD male 45%, female 55%; all CF patients male 55%, female 45%; P= 0.08).
Two other studies had also reported on a female predominance of patients with CFRD9"1 , but were not confirmed by others5' 810'12. As in two other studies1 I 1 1 3, we found a significantly higher proportion of our patients with CFRD with the genotype homozygous delta F508 (78% of patients with CFRD versus 52% of all CF patients; P <0.0001). As this genotype is associated with pancreatic exocrine insufficiency14'15 and pancreatic exocrine insufficiency is associated with pancreatic endocrine dysfunction in CF6177, an association between genotype homozygous delta F508 and pancreatic endocrine dysfunction can be expected. CLASSIFICATION CFRD differs in many aspects from type I and type 2 diabetes. CFRD differs from type 2 diabetes in that patients with CFRD generally present at a young age and are not obese. Unlike type 1 diabetes, autoimmunity is absent18-21.
HLA gene association was not found in one study'9. In another study, an association of CFRD patients with the HLA class II gene HLA-DQB1*0201 (Asp 57-) was found, compared with non-diabetic CF patients and non-CF controls22. Ketoacidosis is exceedingly rare, probably because patients often retain some capacity to secrete insulin. Impaired glucagon secretion may also fail to stimulate ketones formation. Microvascular complications were thought to be rare in the past23'24, but these complications have been described in recent years (see below). Macrovascular complications related to CFRD remain uncommon. In type I diabetes, the requirement of insulin is absolute whereas some patients with CFRD may be treated with oral hypoglycaemic agents (OHAs), at least at an early stage of their disease. At postmortem studies, a higher proportion of patients with CFRD were found to have pancreatic islet amyloid deposition (characteristic of type 2 diabetes) compared with non-diabetic cases25. Thus, CFRD shares some features of both type 1 and type 2 diabetes and should be regarded as a separate entity from both type 1 and type 2 diabetes.
DIAGNOSIS
There is considerable controversy surrounding the methods and strategies used in the diagnosis of CFRD. Various methods have been used in the diagnosis of CFRD, including random and fasting blood glucose3'26'27, periodic measurement of glycosylated haemoglobin (HbAlc)28 and oral glucose tolerance test (OGTT)6'29'30 (see Box 1). The diagnostic values of glucose are originally selected for the diagnosis of diabetes mellitus because in certain high prevalence populations (e.g. the Pima Indians), the glucose concentration at 2 h after a glucose challenge has a bimodal distribution that can be separated into two distinct groups, and also because of the link between glucose concentration at fasting and 2 h, and future risk of microvascular complications33. Whether these diagnostic values also apply to patients with CFRD is unknown, and only a large-scale
longitudinal study will answer this question. At present, these diagnostic values used in the diagnosis of non-CF related diabetes are adopted for the diagnosis of CFRD. Allen and colleagues recently found random blood glucose to be the commonest method used in the diagnosis of CFRD in US centres caring for patients with CF27. However, we have found the use of random blood glucose to be insufficiently sensitive in the diagnosis of CFRD34. We have also found that, even in patients with normal glucose tolerance as defined by OGTT, random blood glucose values can exceed the diagnostic cut-off value of 11.1 mmol/L, provided that a large enough glucose load is given prior to blood sampling35. This may be related to a more rapid absorption of glucose in patients with CF36'37.
The use of random blood glucose as the only method in the diagnosis of CFRD would be inappropriate. In addition, HbAl c has not been found to be sufficiently sensitive in the diagnosis of CFRD6'34.
Recently, the US CF Foundation Consensus Conference on CFRD recommended that the diagnosis of CFRD be based on fasting blood glucose, and that OGTTs should only be performed in patients with symptoms of hyperglycaemia but with normal fasting blood glucose7. However, various studies using OGTT as the gold standard diagnostic method Box 1 Criteria for the diagnosis of diabetes mellitus have suggested that fasting blood glucose has poor sensitivities in the diagnosis of CFRD, ranging from 7% to 25%6,34,38. The use of fasting blood glucose alone in the diagnosis of CFRD would miss a large number of patients with diabetes defined by OGTT who are asymptomatic of hyperglycaemia. The consequence of not diagnosing this large group of patients is unknown. At present, the OGTT is still regarded by many as the gold standard method in the diagnosis of CFRD.
The Danish CF centre recommended that OGTT should be performed annually in those CF patients aged 10 years or over6. However, performing OGTTs on a large number of patients is time and resource consuming, both for patients and staff. We have recently described a more selective approach in performing OGTTs only in patients with one or more of various abnormal screening criteria, including an abnormal random blood glucose (>11.0 mmol/L), HbAlc (> 6.1%), and the presence of symptoms of hyperglycaemia or unexplained weight loss. We have shown that the use of this approach has the potential of identifying the majority of patients with CFRD, without the need to perform OGTTs on all patients. As CFRD occurs almost exclusively in patients with pancreatic exocrine insufficiency (PI), limiting the performance of OGTTs to CF patients with PI will further reduce the number of OGTTs needing to be performed34. The presence of an OGTT-defined diabetic glucose tolerance response in a patient with clear symptoms of hyperglycaemia makes the diagnosis certain. In patients with no symptoms of hyperglycaemia, the OGTT should be repeated and the diagnosis of CFRD should only be made if the second test again reveals diabetic glucose tolerance response. In the UK, there is currently no consensus on the best diagnostic strategy in identifying patients with CFRD.
PATHOGENESIS
The pathogenesis of CFRD is not fully understood but is probably multi-factorial. It is generally accepted that the development of CFRD is mainly as a result of increasing pancreatic fibrosis and fatty infiltration, leading to progressive destruction of pancreatic islet architecture and hence insulin-producing beta cells30'39'40. However, the correlation of islet cell destruction and the degree of pancreatic fibrosis is poor4l'42. In addition, autopsy studies have failed to demonstrate a significantly greater loss in pancreatic islets in patients with CFRD (Table 1) . Differences in the precise methodology and details of the studied subjects (age distribution, clinical status, mixture of different status of glucose tolerance) may account for the divergence in results48 '49 We have studied the contribution of pancreatic beta-cell dysfunction and IR in the pathogenesis of adult patients with CF with an alternative approach using surrogate markers. Pancreatic beta-cell function was assessed using the ratio of 30-min increment of insulin concentration and the 30-min glucose concentration, following an OGTT50. IR was assessed using the homeostasis model assessment for IR (HOMA-IR) (fasting glucose x fasting glucose/22.5)51. We confirmed a progressive decline in pancreatic beta-cell function in CF patients with worsening glucose tolerance. Although we found significantly higher values of HOMA-IR in CF patient groups compared with non-CF controls, these values in CF patients were still considerably lower than values seen in type 2 diabetics, in whom IR plays a prominent role in the pathogenesis of their disease. We concluded that pancreatic beta-cell dysfunction probably plays a more prominent role than IR in the pathogenesis of CFRD52. CLINICAL 
CONSEQUENCES
The relationship between the development of CFRD and a decline in clinical status remains unresolved. CFRD may be a marker of poor clinical and nutritional status, or it may contribute to a decline in patients' clinical status. The question also remains as to whether a 'pre-diabetic' state exists, with progressive decline in clinical status, prior to the development of CFRD. A number of studies have addressed these issues yielding conflicting results. Two studies reported a progressive decline in clinical status in patients prior to the development of CFRD, as compared with non-diabetic CF controls9'53, whereas other studies failed to demonstrate any significant clinical deterioration pre-diagnosis compared with non-diabetic controls8 054. The above studies were retrospective. In a 4-year prospective study, De Luca and colleagues failed to demonstrate a relationship between clinical deterioration and worsening glucose tolerance status55. The decline in clinical status associated with the development of CFRD had been found to be reversed with treatment in one study53.
At present, the question as to whether the development of CFRD is associated with a significant clinical deterioration remains unresolved. If the presence of a pre-diabetic state is confirmed, this would beg the question as to whether specific treatment in this group of pre-diabetic patients would lead to a slower decline in clinical status and a delay in the emergence of diabetes. -DIABETIC COMPLICATIONS Microvascular complications related to CF were regarded as very rare in the past23'24, probably because patients with CFRD did not survive long enough. With the increasing longevity of patients with CF, cases of diabetic microvascular complications have emerged in recent years8'56-59. We have prospectively screened our patients with CFRD for 5 years or more and found a prevalence of diabetic retinopathy of 16% and 23% in patients with CFRD for 5 years or more and 10 years or more, respectively60. Diabetic retinopathy in CF should no longer be regarded as rare and this complication should be screened for at least annually.
Isolated cases of diabetic nephropathy related to CFRD have also been described56 59. Over a 2 month period, we measured the urine albumin to creatinine ratio in unselected clinically stable patients with CFRD attending the Royal Brompton Hospital CF clinic for routine clinic visits61.
Fifteen patients were studied (7 male, 8 female, median age 28). They had CFRD for a median duration of 6 years (range 1-27). We found only one patient (with existing diabetic retinopathy) who had an abnormal albumin/ creatinine ratio. The US CF Foundation Consensus Conference on CFRD currently recommends the screening of patients with CFRD for urine albumin annually7. In our experience, clinically relevant diabetic neuropathy is rare, but this complication should be looked for during the routine check-up of patients with CFRD. As patients with CFRD survive longer, it can be anticipated that the prevalence of diabetic microvascular complications will rise and these complications should be screened for regularly. Macrovascular complications related to CFRD remain exceedingly rare, although isolated cases have been reported62. The rare occurrence of macrovascular complications in CFRD may in part be related to the low lipid absorption secondary to PI and maldigestion in CF patients63.
MANAGEMENT Patients with CF are already spending a considerable amount of time on treatment of their condition. The development of CFRD may be perceived by some patients as yet another hurdle, which can result in non-compliance. In the management of CFRD, it is vitally important for CF care providers to be aware of the differences in CFRD compared with non-CF related diabetes. CF clinicians need to take this factor into account when deciding on treatment regime.
At the authors' unit, following the diagnosis of CFRD, all patients receive individual dietary advice from dietitians specialized in CF. In the management of patients with CFRD, the top priority is to preserve or improve their nutritional and clinical status. The conventional 'diabetic diet' recommended in non-CF diabetes would be inappropriate in CFRD, as the energy provided in such a diet would be insufficient to meet the higher energy requirement of patients with CF. Patients with CFRD are encouraged to eat as much as they can regularly, aiming for 120-150% of the normal energy requirement for their age and sex. A diet high in fat content (aiming for 40% of their total energy intake) is recommended. A regular intake of starchy carbohydrate foods is also encouraged to prevent hypoglycaemia. Refined sugars are allowed to be taken in small amounts in conjunction with other foods, in order to delay absorption, and patients are encouraged to replace sugary snacks with those of a higher fat content (e.g. crisps or nuts). The importance of optimizing nutritional intake is strongly emphasized. We do not advocate the method of 'carbohydrate-counting' as this method would create further burden and complexity to the patients' already complicated treatment programme. We prefer less restriction to patients' diet but instead prescribe enough treatment to control their blood glucose.
As CFRD is an insulinopenic condition, insulin should be regarded as the treatment of choice in the management of CFRD26,53. Some patients with CFRD may retain some residual capacity to secrete insulin, at least in the earlier stages of their disease. OHAs such as sulphonylureas work by augmenting pancreatic insulin secretion and may have a role in the treatment of some patients with CFRD. Indeed, OHAs have been used in some of the UK centres, as well as in centres in Europe and the USA27,64'65. In a retrospective review of all patients with CFRD who attended Royal Brompton Hospital Adult CF clinic over a period of 30 years, we found that approximately two thirds of patients were initially tried on OHAs, with approximately one third of patients requiring to switch to insulin treatment after a median period of 12 months (see Table 2 ). The commonest reason for switching was that patients had persistence of symptoms of hyperglycaemia, high blood glucose profile and weight loss or poor weight gain despite dietary optimization and treatment with OHAs.
At present there is a complete lack of research studies to compare the effects of OHAs versus insulin in the treatment of CFRD and to determine whether any particular group of patients with CFRD may benefit more from one form of treatment compared with another. At the authors' unit, our current policy is that once the diagnosis of CFRD is established, treatment options with either OHAs or insulin are discussed. We recognize that insulin may be the treatment of choice, but for patients who are asymptomatic and clinically well, a trial of OHAs is usually recommended initially, with close monitoring of blood glucose profiles, body weight and lung function at least monthly. OHAs are also used in patients with steroid-induced glucose intolerance and for patients who would find the extra burden of insulin therapy difficult to cope with. The decision as to which form of hypoglycaemic treatment is given, as well as the type of insulin used and the frequency of administration, is made taking into account each patient's condition. Patients who require treatment with insulin are admitted for a few days. A twice-dailv regime of a mixture of short and intermediate acting insulin (e.g. Mixtard 30/70) is a popular choice and patients are taught to self-monitor their blood glucose and to record their glucose profiles in log books. They are advised to monitor their blood glucose daily before each main meal and at bedtime, initially. As their diabetes stabilizes, monitoring can be reduced to twice weekly in those on oral treatment and twice daily in those treated with insulin. We aim for blood glucose levels of 4-7 mmol/L before main meals and 7-10 mmol/L at bedtime. HbA 1 c is checked at regular intervals (once every 3 months or as clinically indicated). There is now evidence to suggest that tight glycaemic control is associated with a lower incidence ofmicrovascular complications in both type 1 and type 2 diabetes66'67. This may also be the case for patients with CFRD. However, efforts in achieving tight glycaemic control have to be weighed against the already busy and tedious treatment regime patients with CFRD have to adhere to. As part of the management plan for patients with CFRD, patients will need to be screened for microvascular complications at least annually.
CONCLUSIONS
As CF patients survive longer, CF care providers will increasingly encounter patients with CFRD. It is vitally important for CF care providers to be aware of the important differences of CFRD compared with non-CF related diabetes. Treatment should aim to ensure preservation or improvement in clinical and nutritional status and quality of life, with minimum disruption and impact on the patients. Further long-term studies are needed to evaluate the current diagnostic methods and criteria. Studies are also needed to examine the role of OHAs compared with insulin in the treatment of CFRD and to identify the group of patients who may benefit more from different forms of treatment. Whether a pre-diabetic state is associated with a clinical deterioration will need to be explored in further large-scale prospective studies.
